Katholieke Universiteit Leuven

The Laboratory of Virology and Chemotherapy of the Katholieke Universiteit Leuven focusses on the development of novel antiviral strategies against a number of  RNA viruses including (but not limited to) HCV, flaviviruses (mainly dengue) and  picornaviruses (rhinovirus inhibitors for the prevention and treatment of exacerbations of asthma and COPD by these viruses).  As partner of the EU FP7 funded project SILVER (Small-molecule Inhibitor Leads Versus Emerging and Neglected Viruses) the laboratory is very active in identifying small molecule inhibitors of yet other (neglected) RNA viruses including  rabies (see below). The laboratory was involved in the discovery of the anti-HCV activity of Alisporivir, a compound which was developed to phase III clinical trials at Novartis